M. G. Castro

Modeling Glioma Oncostreams In Vitro: Spatiotemporal Dynamics of their Formation, Stability, and Disassembly

This paper models glioma oncostreams in vitro, showing their formation, stability, and response to pharmacological agents, with insights into potential anti-invasion targets.

Exploiting the therapeutic vulnerability of IDH-mutant gliomas with zotiraciclib

This paper identifies zotiraciclib as a therapeutic agent targeting IDH-mutant gliomas by disrupting mitochondrial function and inducing oxidative stress, leading to a clinical trial.

Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas

This study shows that ATRX loss primes glioma cells for innate immune recognition, while IDH1R132H mutation suppresses immune signaling, which can be reversed by IDH1 inhibition.

Zinc Finger MYND-Type Containing 8 (ZMYND8) is epigenetically regulated in mutant Isocitrate Dehydrogenase 1 (IDH1) glioma to promote radioresistance

This paper identifies ZMYND8 as a gene epigenetically regulated by mIDH1 that promotes radioresistance in glioma cells, and shows its knockdown enhances radiosensitivity.

Systemic delivery of a CXCR4-CXCL12 signaling inhibitor encapsulated in synthetic protein nanoparticles for glioma immunotherapy

This paper develops synthetic protein nanoparticles delivering a CXCR4 inhibitor to treat glioma by enhancing immunotherapy and reducing tumor progression.

Radiation-reprogrammed glioma stem cells generate vascular-like cells to build a trophic niche driving tumor recurrence

The paper shows radiation induces vascular-like phenotypes in glioma stem cells, creating a trophic niche that promotes tumor recurrence, and identifies P300 inhibition as a potential therapeutic strategy.

Spatiotemporal analysis of glioma heterogeneity reveals Col1A1 as an actionable 1 target to disrupt tumor mesenchymal differentiation, invasion and malignancy

The paper identifies COL1A1 as a key driver of glioma mesenchymal differentiation and invasion, showing its inhibition disrupts tumor structure and improves survival.

G-CSF SECRETED BY EPIGENETICALLY REPROGRAMMED MUTANT IDH1 GLIOMA STEM CELLS REVERSES THE MYELOID CELLS'-MEDIATED IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT

The paper shows that mIDH1 glioma stem cells secrete G-CSF, which reprograms myeloid cells to become non-immunosuppressive, altering the tumor microenvironment.

Systemic Brain Tumor Delivery of Synthetic Protein Nanoparticles for Glioblastoma Therapy

This study develops synthetic protein nanoparticles for GBM therapy, showing they deliver STAT3i siRNA to tumors, enhance radiation response, and induce immune memory in mice.

FYN tyrosine kinase, a downstream target of receptor tyrosine kinases, modulates anti-glioma immune responses

This study shows that FYN tyrosine kinase in glioma cells suppresses anti-glioma immune responses, and its inhibition reduces tumor growth and improves survival in immune-competent models.

Therapeutic efficacy of an immune stimulatory gene therapy strategy in a mouse model of high grade brainstem glioma

This paper tests an immune-stimulatory gene therapy in a mouse model of DIPG, showing increased survival and anti-tumor immunity through adenoviral delivery of TK and Flt3L.

IDH-Tau-EGFR triad defines the neovascular landscape of diffuse gliomas by controlling mesenchymal differentiation

This study identifies the IDH-Tau-EGFR triad as a key factor in defining the neovascular landscape of diffuse gliomas by regulating mesenchymal differentiation and vascular microenvironment.